Tenderwize
Zurück zur Suche

Open-house rebate contracts for Botulinumtoxin Typ A

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Jan 31, 2028 · 524 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Botulinumtoxin Typ A, ATC M03AX21

66/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

66 / 100

Komplexität

58 / 100

Risikofaktoren

The deadline for the first contract start depends on receipt by the buyer, and the notice says access at the buyer is d...

Only paper originals or electronic submission with qualified electronic signature are accepted; other electronic submis...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive rebate contracts for pharmaceutical products containing Botulinumtoxin Typ A (ATC M03AX21).
  • Open-house model with uniform conditions for all participating pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate contracts for Botulinumtoxin Typ A (ATC M03AX21) with AOK Rheinland-Pfalz/Saarland. The contract window runs from 01.04.2026 to 31.03.2028, with monthly entry possible and no selection decision among applicants. Submission is by signed paper originals or by email with qualified electronic signature; electronic submission is otherwise not allowed. The notice explicitly excludes medicines on the BfArM list under § 35 Abs. 5a SGB V (children’s medicines). No contract value is stated.

Risiken

The deadline for the first contract start depends on receipt by the buyer, and the notice says access at the buyer is d...

Only paper originals or electronic submission with qualified electronic signature are accepted; other electronic submis...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Medicines must be approved and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • If a medicine is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided for the contract medicines in distribution at contract conclusion.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate contracts for Botulinumtoxin Typ A

Single lot open-house model for non-exclusive rebate contracts covering medicines with active substance Botulinumtoxin Typ A (ATC M03AX21). The buyer states that all interested pharmaceutical companies may join on equal terms, without individual negotiation or selection. Contract duration is up to 24 months from the earliest start date, with automatic end after 24 months and possible monthly entry. Medicines on the BfArM children’s medicines list are excluded. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Mar 2026 - Mar 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 31, 2028

Vergabedetails

Veröffentlichungsdatum
15 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
110169-2026

Dokumente (1)

Ähnliche Ausschreibungen